news aktuell GmbH

Strides Pharma Consolidates European Business-to-Business Operations in Switzerland

Share
  • Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
  • Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board
Oren Weininger CEO Copyright Strides Pharma International AG
Oren Weininger CEO Copyright Strides Pharma International AG

Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.


Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.


The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.


Oren Weininger
, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”


Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.


For further information, please visit: www.fair-med.com/newsroom

                                                                   
Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690


Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.


Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.

Images

Oren Weininger CEO Copyright Strides Pharma International AG
Oren Weininger CEO Copyright Strides Pharma International AG
Download

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site29.4.2025 14:00:00 CEST | Press Release

The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals. Biomay's recent achievement refers to an inspection by the FDA's Center for Biologics Evaluation and Research (CBER) at Biomay's headquarters manufacturing site in Vienna, Seestadt in December 2024. No observation was found, and no Form FDA 483 was issued by the authority, allowing Biomay's headquarters site to supply Cas9 for the United States. Biomay operates two independent cGMP manufacturing sites, a headquarters facility in Vienna Seestadt, and a second site in Vienna downtown. The authority’s approval of Biomay's headquarters site represents the company's second successful FDA inspection following the 2023 approval of Biomay's

Growth and innovation as cornerstones of a strong democracy and a digitally sovereign Europe29.4.2025 12:00:00 CEST | Pressmeddelande

Germany should be restored to a growth path and should give new impulse to innovation, along with its European partners. Because prosperity is a significant guarantor of a stable democracy. Digital sovereignty is the anchor of a strong Europe. Germany can once again be a country of pioneering innovation and a pacesetter for the continent. For this, comprehensive modernization of the state is indispensable. The Bertelsmann Stiftung presented its proposals at the annual press conference.

Australia’s next government must mend structural cracks appearing in its political, economic and social foundation, report finds25.4.2025 12:05:00 CEST | Pressmeddelande

- Picture is available at AP - Los Angeles/DNA - Australia boasts some of the world’s most sophisticated political institutions and one of its wealthiest economies. But this veneer of success masks deeper structural issues — and a “ticking time bomb” of overreliance on extractive industries must be addressed under Australia’s next government, a new report recommends.

DYMO® LETRATAG 200B VINNER DET PRESTIGEFYLLDA PRISET ”BUSINESS PRODUCT OF THE YEAR” - STRUKTURERAR OCH ORGANISERAR VARDAGEN24.4.2025 16:44:06 CEST | Press Release

Amsterdam – vikten av organisering, effektivitet och produktivitet i både personliga och professionella sammanhang har aldrig varit större. Detta då allt fler använder smarta lösningar för att förenkla sin vardag. DYMO®, en ledande leverantör av innovativa etikett- och utskriftslösningar, ligger här i framkant. Som ett erkännande har DYMO LetraTag 200B belönats med EOPA Best Business Product Award, en utmärkelse som lyfter fram hur den förenklat organisering både hemma och på kontoret. "Trenden mot smart självorganisering fortsätter", berättar Liesbet De Soomer, Global Marketing Director på DYMO. "LetraTag 200B stödjer utveckligen genom att erbjuda en användarvänlig lösning, som gör märkningen snabb och enkel. Med det här verktyget kan användaren strukturera vardagskaoset och organisera tillvaron.” EOPA Best Business Product Award, som delas ut årligen, uppmärksammar produkter som sticker ut för sitt nytänkande, sin funktionalitet och sin användarvänlighet. LetraTag 200B:s utmärkelse b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye